Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Türkiye

Marie Skłodowska-Curie Action · Running

OMNIA OMNIA: Orchestrating Multi-Omic Nanomedicine Insights with AI and Spatial Biology–Driven Innovation and Training for Hard-to-Treat Cancers

Coordinator
Ankara Universitesi, Türkiye
Runs
1 September 2026 to 31 August 2030
Status
Running
EU funding
€1.8m
Total cost
—
Partners
23 organisations in 15 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101299913

What the project is doing

In the project's own words, from its summary on CORDIS.

OMNIA is a European-led, globally connected research and training programme redefining how nanotherapeutics are designed and translated for hard-to-treat cancers. By integrating spatial multi-omics, advanced tumor models, and interpretable AI, OMNIA uncovers how nanoparticles interact with the tumor microenvironment—turning complex molecular data into actionable design rules for safer, more effective treatments. Through a harmonized nanoparticle platform, standardized SOPs, and FAIR-compliant data pipelines, OMNIA transforms fragmented nanomedicine studies into a reproducible, data-driven field.

Its consortium of leading academic, clinical, and industrial partners from Europe, North America, and Asia bridges expertise in materials science, oncology, and AI to deliver open spatial atlases, validated analysis tools, and regulatory-ready templates. At its core, OMNIA is also a training ecosystem. Over 80 researchers will engage in structured, cross-sector secondments—“capsule curricula” that combine hands-on experimentation, AI analysis, and translational science.

This approach cultivates a new generation of scientists fluent in materials–biology–AI integration and capable of driving Europe’s next wave of cancer nanomedicine. Organized into five interconnected work packages spanning nanoparticle design, characterization, spatial biology, AI, and ethics, OMNIA combines scientific excellence, industrial innovation, and mobility-driven collaboration—laying the foundation for a sustainable, spatially informed, AI-enabled future in nanomedicine.

Topics

Who is involved

OrganisationCityCountryRole
Ankara UniversitesiTandogan AnkaraTürkiyeCoordinator
Khalifa University of Science and TechnologyAbu DhabiAEAssociatedpartner
YoursciencebeBruxelles / BrusselBelgiumParticipant
The University of ManitobaManitobaCanadaAssociatedpartner
Fundacio Institut Catala De Nanociencia I NanotecnologiaBellaterra (Barcelona)SpainParticipant
Turun YliopistoTurkuFinlandParticipant
Centre De Lutte Contre Le Cancer Leon BerardLyonFranceParticipant
Centre National De La Recherche Scientifique CNRSParisFranceAssociatedpartner
Institut National De La Sante Et De La Recherche MedicaleParisFranceAssociatedpartner
Universite Lyon 1 Claude BernardVilleurbanne CedexFranceAssociatedpartner
Universita Degli Studi Di PadovaPadovaItalyParticipant
Universita Degli Studi Di SassariSassariItalyParticipant
Pusan National UniversityBusanSouth KoreaAssociatedpartner
Latvijas UniversitateRigaLatviaParticipant
Uniwersytet Im. Adama Mickiewicza WpoznaniuPoznanPolandParticipant
Bluepharma - Industria FarmaceuticasaCoimbraPortugalParticipant
Universidade De CoimbraCoimbraPortugalParticipant
Csd Health CareKyivUkraineParticipant
Materials Research CenterKievUkraineParticipant
The University of BirminghamBirminghamUnited KingdomParticipant
Augusta University Research Institute, Inc.AugustaUnited StatesAssociatedpartner
Drexel UniversityPhiladelphiaUnited StatesAssociatedpartner
University of MiamiCoral Gables MiamiUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI